Summit Therapeutics (SMMT) Receivables (2017 - 2022)

Summit Therapeutics (SMMT) has 6 years of Receivables data on file, last reported at $349000.0 in Q4 2022.

• Quarterly Receivables fell 82.88% year-over-year to $349000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $349000.0 (down 82.88% YoY) and the FY2022 annual result came in at $349000.0, down 82.88% from the prior year.
• Receivables grew to $349000.0 in Q4 2022, from $140000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $22.2 million in Q1 2019 to a low of $140000.0 in Q3 2022.
• A 5-year average of $6.5 million and a median of $2.2 million in 2021 frame the typical range for Receivables.
• Annual changes were most pronounced in 2018 — Receivables jumped 1064.86% — and 2020, when it plunged 97.15%.
• Tracing SMMT's Receivables over 5 years: stood at $19.8 million in 2018, then plunged by 41.4% to $11.6 million in 2019, then sank by 97.15% to $331000.0 in 2020, then soared by 515.71% to $2.0 million in 2021, then plunged by 82.88% to $349000.0 in 2022.
• The last three Receivables figures came in at $349000.0 (Q4 2022), $140000.0 (Q3 2022), and $1.3 million (Q2 2022), per Business Quant data.